Sosei Group Corporation

46 articles with Sosei Group Corporation

• Sosei Heptares and Takeda Enter Into New Strategic Multi-target Research, Development and Commercialization Partnership

  8/5/2019

  Collaboration combines Sosei Heptares' GPCR-focused StaR® and structure-based drug design capabilities with Takeda's discovery, development and therapeutic area expertise

• 

  Sosei Heptares and Takeda Ink $1.2 Billion+ Deal to Develop GPCR Targets

  8/5/2019

  Sosei Group Corporation inked a strategic multi-target partnership with Takeda Pharmaceutical to find, develop and commercialize small molecules and biologics that modulate G protein-coupled receptor targets. The initial focus will be on gastrointestinal targets.

• Sosei Heptares Enters Into Multi-target Research Collaboration and License Agreement With Genentech

  7/16/2019

  Collaboration aims to discover and develop novel medicines that modulate G protein-coupled receptor (GPCR) targets across a range of diseases

• 

  Top 10 Stories of 2018: BioSpace Writers Alex and Mark Pick Their Favorites

  12/19/2018

  In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.

• MiNA Therapeutics Announces Sosei Will Not Exercise Acquisition Option

  10/18/2018

  MiNA Therapeutics remains on track with current development plans for small activating RNA medicines including clinical development of MTL-CEBPA drug candidate

• 

  Allergan and Sosei Halt Alzheimer’s Trial Over Safety Concerns

  9/18/2018

  Allergan and its development partner Sosei Group have voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.

• Sosei Announces Appointment of Chris Cargill as Interim CFO

  6/5/2018

  Sosei Group Corporation announces that Mr. Andrew Oakley, Executive Vice President and CFO, has resigned from the Company.

• 

  AACR Meeting Brief: Sosei, Verseon, Rgenix, Xencor and others

  4/18/2018

  The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.

• Sosei Confirms New Data Demonstrating AZD4635, a Novel A2A Receptor Antagonist, Induces Anti-Tumor Immunity Alone and in Combination With Anti-PD-L1 in Preclinical Models

  4/18/2018

  New data presented at 2018 AACR Meeting

• Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headaches

  3/13/2018

  Sosei Group announced that it has regained worldwide rights from Teva Pharmaceutical Industries Limited to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches.

• Sosei Provides an Update on Its Immuno-Oncology Clinical Program with AstraZeneca

  2/8/2018

  The first patient has been dosed in an expansion cohort in the Phase 1b segment of the Phase 1 study in advanced solid tumours.

• Sosei Announces Restatements of Previously Issued Quarterly and Full Year Accounts

  2/2/2018

  Sosei today announced that it will be restating selected financial statements previously issued by the Company.

• Sosei to Host Investor Day in Tokyo featuring 2017 Nobel Prize Winner Dr. Richard Henderson

  1/26/2018

  Entry on the day will commence from 09:30 a.m.

• 

  Heptares Co-Founder Resigns as VP and CSO of Parent Company Sosei

  1/19/2018

  Dr. Marshall will leave Sosei at the end of February 2018.

• Sosei to Advance Clinical Development in Japan of HTL0018318 in Patients With Dementia With Lewy Bodies (DLB)

  11/9/2017

  Initially, Sosei will undertake a Phase 2 proof-of-concept monotherapy study, expected to begin in Japan in 2018.

• Sosei Group Corporation Subsidiaries Heptares And Jitsubo To Develop Novel GPCR-Targeting Peptide Candidates For Severe Gastro-Intestinal Disorders

  11/10/2016

• Sosei Group Corporation Subsidiary Heptares Awarded $5.5 Million Research & Development Grant From National Institute on Drug Abuse (NIDA)

  9/28/2015

• Sosei Group Corporation Release: Planned Development Of Inhaled Triple Therapy QVM149 For Asthma

  6/18/2015

• Sosei Group Corporation Acquires Jitsubo, A Leading Japanese Peptide Technology Company

  12/12/2014

• Sosei Group Corporation Announces Positive Results For Ultibro® And Seebri® Presented At ERS 2014, And Promotion Agreement With Pfizer Inc. In The UK

  9/8/2014